The MELD score estimates the 3-month survival probability for patients with end-stage liver disease, helping clinicians make critical decisions about treatment and transplantation.
MELD Score Calculator
Mayo End-Stage Liver Disease Prognostic Tool
What is the MELD Score?
The Model for End-Stage Liver Disease (MELD) score is a widely used prognostic scoring system for patients with chronic liver disease. Originally developed to predict mortality risk in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS) procedures, it is now primarily used to prioritize patients for liver transplantation.
The MELD score estimates the 3-month survival probability for patients with end-stage liver disease, helping clinicians make critical decisions about treatment and transplantation.
Clinical Significance
The MELD score has revolutionized liver transplantation by creating an objective, data-driven system for organ allocation. It replaced the previous system that relied heavily on waiting time, helping ensure that the sickest patients receive transplants first.
Calculation Parameters
The MELD score is calculated using three laboratory values:
| Parameter | Significance |
|---|---|
| Serum Bilirubin | Measures liver’s ability to process bile; elevated levels indicate impaired liver function |
| International Normalized Ratio (INR) | Measures blood clotting ability; elevated values indicate impaired synthetic function |
| Serum Creatinine | Measures kidney function; elevated levels may indicate hepatorenal syndrome |
MELD Score Formula
Where “ln” represents the natural logarithm. The score is rounded to the nearest whole number, with a minimum value of 6 and maximum of 40.
Special Considerations
For patients on dialysis twice within the past week, the creatinine value is automatically set to 4.0 mg/dL. Additionally, there are exceptions for certain conditions (like hepatocellular carcinoma) that may increase a patient’s MELD score to reflect their actual transplant urgency.
MELD Score Calculator
Enter the patient’s laboratory values to calculate the MELD score and assess 3-month survival probability.
Score Interpretation
MELD scores are categorized into risk levels with associated 3-month mortality estimates:
Transplant Prioritization
In the United States, the United Network for Organ Sharing (UNOS) uses the MELD score to prioritize patients for liver transplantation:
- MELD ≥ 15: Generally considered for transplant listing
- MELD ≥ 25: High priority for transplantation
- MELD ≥ 35: Highest priority for transplantation
Note: This calculator provides an estimate based on standard MELD calculation. Actual transplant prioritization may include additional factors and exceptions. Always consult with a hepatology specialist for clinical decisions.
The Model for End-Stage Liver Disease (MELD) is a numerically based scoring system used to estimate the 90-day survival probability of patients with chronic liver disease. Originally developed at the Mayo Clinic in 2001 to predict survival in patients undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures, it was adopted by the United Network for Organ Sharing (UNOS) in 2002 as the primary tool for prioritizing patients for liver transplantation (Malinchoc et al., 2000).
The MELD score replaced the older Child-Pugh system because it relies on objective laboratory variables rather than subjective clinical assessments like ascites or encephalopathy.
The MELD Equation
The score is calculated using four biochemical markers that reflect the health of the liver and kidneys. The formula is logarithmic and yields a score ranging from 6 to 40.
The Variables
- Bilirubin: Measures the liver's ability to excrete bile (jaundice).
- Creatinine: Measures kidney function (often impaired in advanced liver disease).
- INR (Prothrombin Time): Measures the liver’s ability to produce blood-clotting proteins.
- Sodium: Added in 2016 (MELD-Na) because low sodium is a potent predictor of mortality in cirrhosis (Kim et al., 2008).
The Formula (MELD-Na)
$$MELD(i) = 0.957 \times \ln(Cr) + 0.378 \times \ln(Bili) + 1.120 \times \ln(INR) + 0.643$$
Note: If the $MELD(i)$ is $> 11$, the score is further adjusted for serum sodium.
Clinical Interpretation and Mortality Risk
In the context of liver transplantation, the "Sickest First" policy applies. A higher MELD score indicates a higher risk of death within three months without a transplant.
| MELD Score | 90-Day Mortality Risk | Clinical Implication |
| < 10 | < 2% | Low priority for transplant |
| 10–19 | 6% | Monitored closely |
| 20–29 | 20% | High priority |
| 30–39 | 53% | Urgent need for transplant |
| > 40 | > 71% | Critical / Immediate urgency |
The Evolution to MELD 3.0
In 2023, the system was updated to MELD 3.0 to address certain disparities. Key changes include:
- Gender Correction: It was discovered that the previous MELD underestimated the risk for women, primarily because women often have lower muscle mass and lower creatinine levels despite having similar kidney function. MELD 3.0 adds points for female candidates (Kim et al., 2021).
- Albumin: Added as an additional marker of liver synthetic function.
- Ceilings: Updated the "cap" for creatinine to better reflect renal dysfunction.
MELD Exceptions
Some patients have a high risk of death or "dropout" from the transplant list that the MELD score does not accurately capture. In these cases, "Exception Points" are granted. The most common exception is Hepatocellular Carcinoma (HCC); these patients are given a standardized MELD score to reflect their cancer urgency, even if their liver function remains relatively stable.
References
- Malinchoc, M., et al. (2000). A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology, 31(4), 864-871. https://doi.org/10.1053/he.2000.5852
- Kim, W. R., et al. (2008). Hyponatremia and mortality among patients on the liver-transplant waiting list. New England Journal of Medicine, 359(10), 1018-1026.
- Kim, W. R., et al. (2021). MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology, 161(6), 1887-1895. https://doi.org/10.1053/j.gastro.2021.08.050
- Wiesner, R., et al. (2003). Model for End-Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology, 124(1), 91-96.
